Prothena Corp Public (PRTA) Cash & Equivalents (2012 - 2026)

Prothena Corp Public's Cash & Equivalents history runs 15 years deep, the most recent figure standing at $329.5 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 21.17% year-over-year to $329.5 million; the TTM figure through Mar 2026 stood at $329.5 million (down 21.17% YoY), while the FY2025 annual figure was $307.5 million, down 34.76% from the prior year.
• Cash & Equivalents was $329.5 million for Q1 2026 at Prothena Corp Public, up from $307.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $710.4 million in Q4 2022 to a low of $307.5 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $514.8 million across 5 years, with a median of $519.3 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents jumped 58.31% in 2022, then tumbled 36.29% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $710.4 million in 2022, then retreated by 12.89% to $618.8 million in 2023, then retreated by 23.83% to $471.4 million in 2024, then tumbled by 34.76% to $307.5 million in 2025, then increased by 7.13% to $329.5 million in 2026.
• The last three Cash & Equivalents figures came in at $329.5 million (Q1 2026), $307.5 million (Q4 2025), and $330.8 million (Q3 2025), per Business Quant data.